In a notable development, the US Food and Drug Administration (FDA) recently published a draft guidance that appears to further refine the idea of evidence of effectiveness, a standard firmly established in 1962 under the US Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act’s “substantial evidence” requirement serves as the decisive measure for the approval of all drugs and biologics within the United States.
Due to its robust requirements, the FDA’s approval standard is frequently considered to be the international “gold standard” for approving drugs. However, the recent draft guidance indicates that the FDA is not satisfied to rest on their laurels. The newly issued draft guidance seeks to refine the existing standard, suggesting that the FDA continues to adapt to new information and developments in the pharmaceutical industry.
Substantial evidence, as defined previously, involves rigorous controlled investigations by qualified experts ensuring the effectiveness of a drug under adequate procedures. This standard effectively ensured the safety and efficacy of novel drugs hitting the market, playing an instrumental role in safeguarding public health.
The details of how the FDA intends to revise or augment this tried-and-true standard have not been clearly spelled out. As it stands, legal experts, FDA-watchers, and stakeholders in the pharmaceutical industry have much to anticipate as the FDA moves forward with this process.
The evolution of this standard is of unquestionable significance to anyone involved in the development, testing, and sale of drugs and biologics, demonstrating the need for careful monitoring as this process progresses.